Evaluation of clopidogrel responsiveness after drug-eluting stent implantation

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Clopidogrel is crucial for preventing ischemic events in cardiovascular disease patients, particularly after acute coronary syndrome or percutaneous coronary intervention (PCI).
• Dual antiplatelet therapy (aspirin and a thienopyridine) is standard after drug-eluting stent implantation.
• Individual responses to clopidogrel vary, with poor response linked to adverse outcomes like stent thrombosis.

Purpose of the Study:

• To highlight the clinical utility of platelet function assays in managing clopidogrel therapy.
• To emphasize the need for understanding assay methodologies, result interpretation, and treatment strategies for non-responders.
• To inform about ongoing trials evaluating individualized antiplatelet therapy based on platelet function testing.

Main Methods:

• Review of clopidogrel's role in cardiovascular disease and PCI.
• Discussion of pharmacokinetic and pharmacodynamic variability.
• Examination of available platelet function assay methodologies and their clinical integration.
• Overview of treatment adjustments for patients with suboptimal clopidogrel response.

Main Results:

• Significant inter-individual variability exists in clopidogrel pharmacokinetics and pharmacodynamics.
• Suboptimal clopidogrel response is associated with increased risk of adverse cardiovascular events, including drug-eluting stent thrombosis.
• Platelet function testing enables clinical assessment of clopidogrel response.

Conclusions:

• Platelet function testing is a valuable tool for guiding individualized antiplatelet therapy in patients undergoing PCI.
• Understanding and utilizing platelet function assays can optimize clopidogrel therapy and mitigate risks.
• Personalized antiplatelet strategies based on platelet function testing show promise in reducing ischemic events.